Company profile
PROTHENA CORP PUBLIC LTD CO
NASDAQ:PRTABiotechnology: Pharmaceutical Preparations
Drug pipeline (4)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| BIRTAMIMAB | phase3 | — | 5 | completed, terminated |
| Coramitug | phase1 | — | 1 | terminated |
| IMAPRELIMAB | phase1 | — | 2 | no active trials |
| PRASINEZUMAB | phase1 | — | 2 | no active trials |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (12)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT03336580 | phase1 | terminated | 2018-04-05 | 2020-07-23 | Prothena Biosciences Limited | A Study of PRX004 in Subjects With Amyloid Transthyretin (ATTR) Amyloidosis |
| NCT04973137 | phase3 | terminated | 2021-08-30 | 2025-04-02 | Prothena Biosciences Ltd. | A Study to Evaluate the Efficacy and Safety of Birtamimab in Mayo Stage IV Patients With AL Amyloidosis |
| NCT02157714 | phase1 | completed | 2014-06-01 | 2016-09-01 | Prothena Biosciences Limited | Multiple Ascending Dose Study of PRX002 in Patients With Parkinson's Disease |
| NCT02630901 | phase1 | completed | 2016-03-17 | 2018-02-28 | Prothena Biosciences Limited | Multiple Ascending Dose Study of PRX003 in Subjects With Psoriasis |
| NCT02613182 | phase2 | terminated | 2016-02-01 | 2018-05-01 | Prothena Biosciences Ltd. | Open-label Extension Study of NEOD001 in Subjects With Light Chain (AL) Amyloidosis |
FDA applications (0)
No records yet.